{"id":2001,"date":"2023-04-06T10:23:35","date_gmt":"2023-04-06T07:23:35","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=2001"},"modified":"2023-04-06T10:25:22","modified_gmt":"2023-04-06T07:25:22","slug":"tanidan-tedaviye-kadar-her-anlarinda-kanser-hastalarinin-yanindayiz","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=2001","title":{"rendered":"<strong>Tan\u0131dan Tedaviye Kadar Her Anlar\u0131nda Kanser Hastalar\u0131n\u0131n Yan\u0131nday\u0131z<\/strong>"},"content":{"rendered":"<div class=\"wp-block-image\">\n<figure class=\"alignleft is-resized\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2023\/04\/1L3A5258-1.jpg\" alt=\"\" class=\"wp-image-2010\" width=\"231\" height=\"151\" srcset=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2023\/04\/1L3A5258-1.jpg 1324w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2023\/04\/1L3A5258-1-300x197.jpg 300w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2023\/04\/1L3A5258-1-1024x674.jpg 1024w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2023\/04\/1L3A5258-1-768x505.jpg 768w\" sizes=\"(max-width: 231px) 100vw, 231px\" \/><\/figure><\/div>\n\n\n<p>2025 global inovatif sa\u011fl\u0131k \u015firketi olma vizyonu do\u011frultusunda onkoloji &amp; hematoloji tedavi alan\u0131nda; meme kanseri, l\u00f6semi &amp; lenfomalar, kemoterapi ve di\u011fer tedavilere ba\u011fl\u0131 spesifik organ-doku hasar\u0131ndan koruyucu tedaviler ve malign olmayan hematolojik nadir, \u00f6l\u00fcmc\u00fcl hastal\u0131klar\u0131n tedavisinde kullan\u0131lan ila\u00e7lar\u0131 T\u00fcrkiye ve uluslararas\u0131 pazarlarda kullan\u0131ma sunmak \u00fczere \u00e7al\u0131\u015fan TRPharm\u2019\u0131n Onkoloji &amp; Hematoloji \u0130\u015f Birimi y\u00f6neticileri ile\u00a0 bu alandaki \u00e7al\u0131\u015fmalar\u0131n\u0131 konu\u015ftuk.<\/p>\n\n\n\n<p><strong>TRPharm\u2019\u0131n onkoloji &amp; hematoloji ekibini biraz tan\u0131yabilir miyiz?<\/strong><\/p>\n\n\n\n<p><strong>&nbsp;Onkolog Do\u00e7. Dr. Tolga Tun\u00e7el &#8211; Medikal Direkt\u00f6r<\/strong><\/p>\n\n\n\n<p>2001 y\u0131l\u0131nda G\u00fclhane Askeri T\u0131p Fak\u00fcltesi\u2019nden mezun oldum. Haydarpa\u015fa Gata E\u011fitim Ara\u015ft\u0131rma Hastanesi\u2019nde i\u00e7 hastal\u0131klar\u0131 ve t\u0131bb\u0131 onkoloji uzmanl\u0131\u011f\u0131m\u0131 ald\u0131ktan sonra 2015 y\u0131l\u0131nda ila\u00e7 firmas\u0131nda onkoloji alan\u0131nda grup medikal m\u00fcd\u00fcr olarak \u00e7al\u0131\u015fmaya ba\u015flad\u0131m. 2016 y\u0131l\u0131nda do\u00e7entlik unvan\u0131n\u0131 ald\u0131m ve yakla\u015f\u0131k 7 y\u0131ld\u0131r TRPharm ila\u00e7 firmas\u0131nda medikal direkt\u00f6r olarak \u00e7al\u0131\u015f\u0131yorum. Medikal departman olarak gerek T\u00fcrkiye gerekse MENA b\u00f6lgesinde onkoloji &amp; hematoloji, romatoloji ve nadir haftal\u0131klarda inovatif \u00fcr\u00fcnlerin hastalara ula\u015fmas\u0131na \u00e7al\u0131\u015fmaktay\u0131z.&nbsp;<\/p>\n\n\n\n<p>T\u00fcrkiye\u2019de haklar\u0131n\u0131 sahip oldu\u011fumuz bu inovatif \u00fcr\u00fcnlerin faz I ve faz II \u00e7al\u0131\u015fmalar\u0131n\u0131 ba\u015flatt\u0131k ve bu \u00fcr\u00fcnlerinde k\u0131sa s\u00fcrede hastalara ula\u015fmas\u0131 i\u00e7in ak\u0131lc\u0131 \u00e7\u00f6z\u00fcmler departman\u0131m\u0131n\u0131z olarak var g\u00fcc\u00fcm\u00fczle&nbsp;\u00e7al\u0131\u015f\u0131yoruz<\/p>\n\n\n\n<p><strong>Nazl\u0131can I\u015f\u0131tman- Pazarlama Direkt\u00f6r\u00fc<\/strong><\/p>\n\n\n\n<p>\u0130T\u00dc Kimya M\u00fchendisli\u011fi mezunuyum. \u00dcr\u00fcn y\u00f6netimi ve pazarlama alan\u0131nda y\u00fcksek lisans yapt\u0131m. 20 y\u0131ld\u0131r ila\u00e7 sekt\u00f6r\u00fcnde, sat\u0131\u015f ve pazarlama y\u00f6neticisi olarak \u00e7al\u0131\u015f\u0131yorum. Yakla\u015f\u0131k 1,5 y\u0131ld\u0131r TRPharm tak\u0131m\u0131nda pazarlama direkt\u00f6r\u00fc olarak g\u00f6rev yap\u0131yorum. TRPharm\u2019\u0131n faaliyet g\u00f6sterdi\u011fi t\u00fcm \u00fclkelerde ve tedavi alanlar\u0131nda hekimlere, hastalara ve partnerlerimize sundu\u011fumuz \u00e7\u00f6z\u00fcmlerle k\u00f6pr\u00fc olma misyonuna katk\u0131da bulundu\u011fum&nbsp;i\u00e7in&nbsp;mutluyum.<\/p>\n\n\n\n<p><strong>Levent Da\u011fl\u0131o\u011flu &#8211; \u00dcr\u00fcn M\u00fcd\u00fcr\u00fc<\/strong><\/p>\n\n\n\n<p>Eski\u015fehir Osmangazi \u00dcniversitesi Kimya B\u00f6l\u00fcm\u00fc mezunuyum, sonras\u0131nda Bilgi \u00dcniversitesi\u2019nde MBA program\u0131n\u0131 tamamlad\u0131m. 18 y\u0131ll\u0131k ila\u00e7 end\u00fcstrisi deneyimine sahibim. 2017 y\u0131l\u0131ndan bu yana TRPharm \u0130la\u00e7 \u2019ta g\u00f6rev yap\u0131yorum. 15 y\u0131l nadir hastal\u0131klar alan\u0131nda sat\u0131\u015f ve pazarlaman\u0131n farkl\u0131 rollerinde g\u00f6rev yapt\u0131m. \u015eu an TRPham\u2019da farkl\u0131 sorumluluklar\u0131m ile onkoloji &amp; hematoloji tedavi alan\u0131nda \u00fcr\u00fcn y\u00f6neticisi olarak \u00e7al\u0131\u015f\u0131yorum.<\/p>\n\n\n\n<p>TRPharm Onkoloji &amp; Hematoloji Tedavi Alan\u0131\u2019nda ekibimizle birlikte, toplum ve payda\u015flar\u0131m\u0131za duydu\u011fumuz sorumluluk ile hasta ve hasta yak\u0131nlar\u0131na umut, hekimlere ve t\u00fcm sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131 ile s\u00fcrd\u00fcr\u00fclebilir i\u015f birli\u011fi kurmak i\u00e7in \u00e7al\u0131\u015f\u0131yorum.&nbsp;<\/p>\n\n\n\n<p><strong>Dr. Erg\u00fcne\u015f Kayao\u011flu &#8211; Medikal M\u00fcd\u00fcr<\/strong><\/p>\n\n\n\n<p>Onkoloji &amp; hematoloji tedavi alan\u0131nda medikal m\u00fcd\u00fcr olarak \u00e7al\u0131\u015f\u0131yorum. Cerrahpa\u015fa T\u0131p Fak\u00fcltesi\u2019nden mezun oldum sonras\u0131nda \u00f6zel sa\u011fl\u0131k sigortas\u0131 firmas\u0131nda dan\u0131\u015fman hekim ve medikal direkt\u00f6r olarak g\u00f6rev ald\u0131m. Mecburi hizmeti takiben ila\u00e7 sekt\u00f6r\u00fcne girdim onkoloji, hematoloji, nadir hastal\u0131klar, kardiyoloji alanlar\u0131 ba\u015fta olmak \u00fczere pek \u00e7ok farkl\u0131 alanda 11 y\u0131ll\u0131k deneyim sahibi oldum. TRPharm\u2019da g\u00f6rev yapt\u0131\u011f\u0131m 2 y\u0131lda, sekt\u00f6rde kazand\u0131\u011f\u0131m bu deneyimi yine sekt\u00f6rde alan\u0131nda en etkin ve ba\u015far\u0131l\u0131 ekip arkada\u015flar\u0131m\u0131n deneyimleriyle harmanlay\u0131p, hastalar\u0131n kar\u015f\u0131lanmam\u0131\u015f medikal ihtiya\u00e7lar\u0131na \u00e7\u00f6z\u00fcm \u00fcretmek ve hastalar\u0131 g\u00fcncel tedavilerle bulu\u015fturmak i\u00e7in \u00e7al\u0131\u015f\u0131yorum. Bu tak\u0131m\u0131n bir par\u00e7as\u0131 olmaktan dolay\u0131 b\u00fcy\u00fck bir mutluluk&nbsp;duyuyorum.<\/p>\n\n\n\n<p><strong>Op. Dr. Volkan Kaya &#8211; Medikal M\u00fcd\u00fcr<\/strong><\/p>\n\n\n\n<p>Onkoloji &amp; hematoloji tedavi alan\u0131nda medikal m\u00fcd\u00fcr olarak \u00e7al\u0131\u015f\u0131yorum. Trakya \u00dcniversitesi T\u0131p Fak\u00fcltesi mezunuyum. Meslek hayat\u0131m\u0131n ba\u015flar\u0131nda acil servis ve z\u00fchrevi hastal\u0131klar alanlar\u0131nda pratisyen hekim olarak \u00e7al\u0131\u015ft\u0131m, Bak\u0131rk\u00f6y Dr. Sadi Konuk E\u011fitim ve Ara\u015ft\u0131rma Hastanesi\u2019nde acil t\u0131p uzmanl\u0131\u011f\u0131 ihtisas\u0131m\u0131 2. y\u0131l\u0131nda b\u0131rakt\u0131ktan sonra Taksim E\u011fitim ve Ara\u015ft\u0131rma Hastanesi Ortopedi ve Travmatoloji Klini\u011fi\u2019nde ihtisas\u0131m\u0131 tamamlad\u0131m. \u0130la\u00e7 sekt\u00f6r\u00fcnde hematoloji, onkoloji ve kardiyovask\u00fcler alanlarda deneyim kazand\u0131m. 20 y\u0131ll\u0131k t\u0131bbiyeli olarak \u015fimdiye kadar gerek teorik gerek pratik bilgi birikimimi do\u011fru hastaya, do\u011fru tedavinin do\u011fru zamanda ula\u015ft\u0131r\u0131lmas\u0131na adad\u0131m. TRPharm\u2019da, hepsi birbirinden deneyimli tak\u0131m arkada\u015flar\u0131m ve sahadaki kutsal meslekta\u015flar\u0131m ile bu amac\u0131 her g\u00fcn bir ad\u0131m ileriye ta\u015f\u0131man\u0131n mesleki tatminini&nbsp;ya\u015f\u0131yorum.<\/p>\n\n\n\n<p><strong>Hakan \u00d6zdemirel &#8211; \u0130\u015f Segmenti Lideri<\/strong><\/p>\n\n\n\n<p>Anadolu \u00dcniversitesi \u0130.\u0130.B.F. \u00c7al\u0131\u015fma Ekonomisi ve End\u00fcstri \u0130li\u015fkileri B\u00f6l\u00fcm\u00fc mezunuyum. Mezuniyetimin ard\u0131ndan, 26 y\u0131l \u00f6nce ila\u00e7 end\u00fcstrisinde g\u00f6reve ba\u015flad\u0131m. Bu s\u00fcre zarf\u0131nda global ve yerli ila\u00e7 firmalar\u0131nda farkl\u0131 pozisyonlarda g\u00f6rev yapt\u0131m. Uzun s\u00fcreli ila\u00e7 end\u00fcstrisi tecr\u00fcbemin b\u00fcy\u00fck bir b\u00f6l\u00fcm\u00fcn\u00fc onkoloji &amp; hematoloji tedavi alan\u0131nda yer alan tedavilere y\u00f6nelik olarak ger\u00e7ekle\u015ftirdim.&nbsp;<\/p>\n\n\n\n<p>2016 y\u0131l\u0131nda TRPharm\u2019da g\u00f6reve ba\u015flad\u0131m. TRPharm\u2019\u0131n geli\u015fimine ba\u011fl\u0131 olarak zenginle\u015fen \u00fcr\u00fcn portf\u00f6y\u00fcm\u00fcz do\u011frultusunda, nadir hastal\u0131klar ve di\u011fer tedavi alanlar\u0131nda da TRPharm\u2019\u0131n vizyonuna ve geli\u015fimine katk\u0131da bulunabilmek amac\u0131yla elinden gelenin fazlas\u0131n\u0131 yapabilme motivasyonuyla bir araya gelen bu tak\u0131m\u0131n bir \u00fcyesi olmaktan gurur ve mutluluk&nbsp;duymaktay\u0131m.<\/p>\n\n\n\n<p><strong>TRPharm\u2019\u0131n onkoloji &amp; hematoloji vizyonundan bahseder misiniz?<\/strong><\/p>\n\n\n\n<p>TRPharm, onkoloji &amp; hematoloji tedavi alan\u0131nda inovasyonu, sa\u011fl\u0131k ihtiya\u00e7lar\u0131 ile bulu\u015fturan platform olmay\u0131 kendisine ama\u00e7 edinmi\u015ftir. Bu s\u00fcre\u00e7te d\u00fcnyan\u0131n bir\u00e7ok k\u00f6\u015fesindeki \u015firketlerle partnerliklerimiz mevcuttur. Bu partnerlikler inovasyonun lisanslanmas\u0131 odakl\u0131 oldu\u011fu gibi, inovasyonunun yarat\u0131lmas\u0131 i\u00e7in gereken Ar-Ge s\u00fcre\u00e7lerini de i\u00e7ermektedir. Bu alanda T\u00fcrkiye i\u00e7indeki partnerliklerimiz de h\u0131zla artmaktad\u0131r.<\/p>\n\n\n\n<p>TRPharm\u2019\u0131n vizyonunda global ve inovatif sa\u011fl\u0131k \u015firketi olmak var. Onkoloji &amp; hematoloji tedavi alan\u0131 vizyonumuz da \u015firket vizyonu ile paralel bir konumdad\u0131r. TRPharm olarak kanser hastalar\u0131n\u0131n tan\u0131s\u0131ndan tedavisine kadar her ad\u0131mda yanlar\u0131nda yer almay\u0131 hedeflemekteyiz. Bundan dolay\u0131 \u015firket b\u00fcnyemizde Diagnostik \u0130\u015f Birimi\u2019ni kurarak tedavilere ek olarak tan\u0131sal hizmetlerde de bir k\u00f6pr\u00fc olma misyonumuzu s\u00fcrd\u00fcrmekteyiz.<\/p>\n\n\n\n<p><strong>TRPharm onkoloji &amp; hematoloji alanlar\u0131nda hangi tedavileri oda\u011f\u0131na al\u0131yor?<\/strong><\/p>\n\n\n\n<p>TRPharm olarak 2025 global inovatif sa\u011fl\u0131k \u015firketi olma vizyonu do\u011frultusunda onkoloji &amp; hematoloji tedavi alan\u0131nda; meme kanseri, l\u00f6semi &amp; lenfomalar, kemoterapi ve di\u011fer tedavilere ba\u011fl\u0131 spesifik organ-doku hasar\u0131ndan koruyucu tedaviler ve malign olmayan hematolojik nadir, \u00f6l\u00fcmc\u00fcl hastal\u0131klar\u0131n tedavisinde kullan\u0131lan ila\u00e7lar\u0131 T\u00fcrkiye ve uluslararas\u0131 pazarlarda payda\u015flar\u0131m\u0131z\u0131n kullan\u0131m\u0131na sunmak \u00fczere \u00e7al\u0131\u015f\u0131yoruz.<\/p>\n\n\n\n<p><strong>2023 y\u0131l\u0131 boyunca odaklanaca\u011f\u0131n\u0131z \u00f6ncelikli g\u00fcndem maddeleriniz neler olacak? Bunun yan\u0131 s\u0131ra uzun vadeli hedeflerinizden de s\u00f6z eder misiniz?<\/strong><\/p>\n\n\n\n<p>TRPharm Onkoloji &amp; Hematoloji Tak\u0131m\u0131 olarak, i\u015fimizi hep tutkuyla yapt\u0131k. 2023\u2019te de ayn\u0131 \u015fekilde devam edece\u011fiz ve \u00fcr\u00fcnlerimizi faaliyet g\u00f6sterdi\u011fimiz \u00fclkelerde hastalarla bulu\u015fturmak \u00e7al\u0131\u015faca\u011f\u0131z.<\/p>\n\n\n\n<p>\u0130la\u00e7 sekt\u00f6r\u00fc, \u00fclkeler i\u00e7in en \u00f6nemli sekt\u00f6rlerden biridir. \u0130la\u00e7ta d\u0131\u015fa ba\u011f\u0131ml\u0131l\u0131\u011f\u0131n olmamas\u0131n\u0131n T\u00fcrkiye i\u00e7in olduk\u00e7a \u00f6nemli oldu\u011funu d\u00fc\u015f\u00fcn\u00fcyoruz. Bu anlamda ila\u00e7lar\u0131n T\u00fcrkiye\u2019de cell-line\u2019dan itibaren \u00fcretilebiliyor olmas\u0131 biyobenzerlerde gelmemiz gereken en \u00f6nemli noktad\u0131r. TRPharm\u2019\u0131n Dr. Reddy\u2019s ile dahil oldu\u011fu s\u00fcre\u00e7, bu \u00fcr\u00fcnlerin cell-line\u2019dan itibaren \u00fcretilmesini i\u00e7ermektedir. Bu biyobenzer \u00fcr\u00fcnlerin \u00fclkeye kazand\u0131r\u0131lmas\u0131 ve burada sa\u011flanan maliyetlerdeki avantajlar \u00f6n\u00fcm\u00fcze birtak\u0131m f\u0131rsatlar \u00e7\u0131kartacakt\u0131r.<\/p>\n\n\n\n<p>2023 y\u0131l\u0131 ve sonras\u0131nda kanser tedavilerinde orijinal ve kaliteli jenerik \u00fcr\u00fcnlerin T\u00fcrkiye ve uluslararas\u0131 pazarlarda eri\u015filebilir olmas\u0131 i\u00e7in lokal ve yurt d\u0131\u015f\u0131 i\u015f birli\u011fi \u00e7al\u0131\u015fmalar\u0131m\u0131za devam ediyoruz.<\/p>\n\n\n\n<p><strong>TRPharm\u2019\u0131n sosyal sorumluluk ve s\u00fcrd\u00fcr\u00fclebilirlik anlay\u0131\u015f\u0131ndan k\u0131saca bahseder misiniz? Yak\u0131n zamanda ya\u015fad\u0131\u011f\u0131m\u0131z deprem felaketinde b\u00f6lgeye destek sa\u011flamak ad\u0131na TRPharm olarak neler yapt\u0131n\u0131z?<\/strong><\/p>\n\n\n\n<p>TRPharm\u2019da 2023 Ocak ay\u0131nda So-So isminde bir sosyal sorumluluk kul\u00fcb\u00fc kurduk. Kul\u00fcb\u00fcm\u00fcz\u00fcn felsefesi, de\u011ferlerimizden ya\u015fam ilkesiyle hareket ederek d\u00fcnyam\u0131z\u0131 payla\u015ft\u0131\u011f\u0131m\u0131z t\u00fcm canl\u0131lara y\u00f6nelik projeler hayata ge\u00e7irmek ve s\u00fcrd\u00fcr\u00fclebilirlik hassasiyeti ile hareket etmektir. Bu amaca y\u00f6nelik yol haritam\u0131z\u0131 belirledi\u011fimiz ve \u00e7al\u0131\u015fmalar\u0131m\u0131za ba\u015flad\u0131\u011f\u0131m\u0131z g\u00fcnlerde \u00e7ok ac\u0131d\u0131r ki, bizi derinden yaralayan deprem felaketi nedeniyle kenetlendik.<\/p>\n\n\n\n<p>H\u0131zl\u0131 ve organize olman\u0131n en \u00f6nemli ihtiya\u00e7 oldu\u011funun bilinciyle TRPharm \u00e7al\u0131\u015fanlar\u0131n\u0131n da deste\u011fiyle ilk faaliyetimiz nakdi ba\u011f\u0131\u015f yapabilme konusunda bir fon olu\u015fturmak oldu. Ba\u011f\u0131\u015flar\u0131 AHBAP,&nbsp;AKUT,&nbsp;AFAD, TTOD arac\u0131l\u0131\u011f\u0131yla b\u00f6lgeye ula\u015ft\u0131rd\u0131k. B\u00f6lgede bulunan ve b\u00f6lgeye ula\u015fan \u00e7al\u0131\u015fanlar\u0131m\u0131z arac\u0131l\u0131\u011f\u0131yla arama kurtarma ekipman\u0131 ve ila\u00e7 deste\u011fi sa\u011flad\u0131k. IEIS ve AIFD arac\u0131l\u0131\u011f\u0131yla \u0130la\u00e7, DEIK arac\u0131l\u0131\u011f\u0131yla konteyner deste\u011fi sa\u011flad\u0131k. Afet b\u00f6lgesinde ihtiya\u00e7lar\u0131n \u00e7ok fazla ve her ge\u00e7en g\u00fcn de\u011fi\u015fkenlik g\u00f6sterdi\u011finin bilinciyle yard\u0131mlar\u0131m\u0131z\u0131 s\u00fcrd\u00fcr\u00fclebilir olacak \u015fekilde planlamaya devam ediyoruz.<\/p>\n\n\n\n<p>Ayr\u0131ca sosyal sorumluluk faaliyetlerimiz kapsam\u0131nda, \u00e7al\u0131\u015fanlar\u0131m\u0131z\u0131n do\u011fum g\u00fcnlerinde TEMA ile \u00e7al\u0131\u015farak a\u011fa\u00e7 dikilmesini sa\u011fl\u0131yor, \u00e7al\u0131\u015fanlar\u0131m\u0131z yak\u0131nlar\u0131n\u0131 kaybetti\u011finde Dar\u00fc\u015f\u015fafaka&#8217;ya ba\u011f\u0131\u015f yap\u0131yoruz. Bununla birlikte, ya\u015fam de\u011ferimiz ve s\u00fcrd\u00fcr\u00fclebilirlik bak\u0131\u015f a\u00e7\u0131s\u0131 ile d\u00fcnyaya b\u0131rakt\u0131\u011f\u0131m\u0131z karbon ayak izimizi k\u00fc\u00e7\u00fcltmek i\u00e7in yeni projemizi hayata ge\u00e7irmeye haz\u0131rlan\u0131yoruz.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>2025 global inovatif sa\u011fl\u0131k \u015firketi olma vizyonu do\u011frultusunda onkoloji &#038; hematoloji tedavi alan\u0131nda; meme kanseri, l\u00f6semi &#038; lenfomalar, kemoterapi ve di\u011fer tedavilere ba\u011fl\u0131 spesifik organ-doku hasar\u0131ndan koruyucu tedaviler ve malign olmayan hematolojik nadir, \u00f6l\u00fcmc\u00fcl hastal\u0131klar\u0131n tedavisinde kullan\u0131lan ila\u00e7lar\u0131 T\u00fcrkiye ve uluslararas\u0131 pazarlarda kullan\u0131ma sunmak \u00fczere \u00e7al\u0131\u015fan TRPharm\u2019\u0131n Onkoloji &#038; Hematoloji \u0130\u015f Birimi y\u00f6neticileri ile\u00a0 bu alandaki \u00e7al\u0131\u015fmalar\u0131n\u0131 konu\u015ftuk.<\/p>\n","protected":false},"author":1,"featured_media":2013,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,2],"tags":[85,76,83,89],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/2001"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2001"}],"version-history":[{"count":1,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/2001\/revisions"}],"predecessor-version":[{"id":2011,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/2001\/revisions\/2011"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/2013"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2001"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2001"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}